Regeneron antibody secures FDA win; Yancopoulos in expansive Q&A; Biogen’s Reata bidding war details revealed; Peter Marks on accelerated approvals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With most sec­ond quar­ter earn­ings in the rearview mir­ror, we’ve been lock­ing in in­ter­views with key fig­ures in biotech and phar­ma. While we have more Q&As in the pipeline, we’ll ask you this ques­tion: Who would you like us to chat with? Email us to have your say. — Rey­nald Cas­tañe­da

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.